Patient-reported outcomes in moderate-to-severe allergic asthmatics treated with omalizumab: a systematic literature review of randomized controlled trials

Jonathan Corren, Abhishek Kavati, Benjamin Ortiz, Ashok Vegesna, Jennifer A. Colby, Kimberly Ruiz, Reynold A. Panettieri

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations

Abstract

Objective: Randomized controlled trials (RCTs) have established the safety and efficacy of omalizumab on clinical parameters, and have also evaluated its impact on patient-reported outcomes (PROs). The purpose of this systematic literature review was to review published data based on PRO endpoints in order to determine the benefit of omalizumab as add-on therapy to inhaled corticosteroids in patients with moderate-to-severe persistent allergic asthma. Methods: A systematic literature review was conducted of reference databases and recent conferences. RCTs of add-on omalizumab therapy in adults, adolescents, and children with moderate-to-severe persistent asthma were included. Two researchers independently screened and reviewed articles with regards to inclusion and exclusion criteria for relevant studies. Results: Twenty-six trials met the criteria for inclusion. Of these, PRO measures were included in 19 trials to capture the impact of omalizumab on symptoms, 11 assessed patients for health-related quality-of-life (HRQoL), and four evaluated asthma control. Other PROs related to global evaluation of treatment effectiveness and work productivity. Overall, results demonstrated a significant difference across most PROs in favor of omalizumab add-on therapy vs placebo or comparators. Conclusions: PROs are an integral part of outcome assessment in clinical trials related to asthma. The RCTs reviewed demonstrate that omalizumab treatment improves PROs in patients with moderate-to-severe persistent allergic asthma, particularly symptom control and HRQoL.

Original languageEnglish (US)
Pages (from-to)65-80
Number of pages16
JournalCurrent Medical Research and Opinion
Volume34
Issue number1
DOIs
StatePublished - Jan 2 2018

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Keywords

  • IgE response underlying allergic asthma and rhinitis
  • allergic asthma
  • omalizumab
  • patient reported outcome measures
  • patient reported outcomes

Fingerprint

Dive into the research topics of 'Patient-reported outcomes in moderate-to-severe allergic asthmatics treated with omalizumab: a systematic literature review of randomized controlled trials'. Together they form a unique fingerprint.

Cite this